Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;94(6):875-80.
doi: 10.3324/haematol.2008.002691. Epub 2009 Mar 31.

CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK

Mark Bower  1 , Martin Fisher, Teresa Hill, Iain Reeves, John Walsh, Chloe Orkin, Andrew N Phillips, Loveleen Bansi, Richard Gilson, Philippa Easterbrook, Margaret Johnson, Brian Gazzard, Clifford Leen, Deenan Pillay, Achim Schwenk, Jane Anderson, Kholoud Porter, Mark Gompels, Caroline A Sabin; UK CHIC Steering Committee
Collaborators, Affiliations

CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK

Mark Bower et al. Haematologica. 2009 Jun.

Abstract

Since the introduction of highly active antiretroviral therapy, there has been a decline in the incidence of non-Hodgkin's lymphoma among HIV-infected individuals. We described trends in the incidence of systemic non-Hodgkin's lymphoma in the UK CHIC Study from 1996-2006 and evaluated the association between immunosuppression and development of systemic non-Hodgkin's lymphoma: 286/23,155 (1.2%) individuals developed an AIDS-defining lymphoma (258 systemic). Younger age, receipt of highly active antiretroviral therapy and later calendar year were all independently associated with a reduced risk of systemic non-Hodgkin's lymphoma. A lower latest CD4 count was strongly associated with systemic non-Hodgkin's lymphoma, in patients who had (RR per log(2)(cells/mm(3)) higher: 0.62) and had not (0.70) received highly active antiretroviral therapy. Associations with other measures of immunosuppression, including nadir CD4 count, experience and duration of severe immunosuppression, were generally weaker. Earlier highly active anti-retroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma.

PubMed Disclaimer

References

    1. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi’s sarcoma and Non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J. 1999;319:23–4. - PMC - PubMed
    1. Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22:2177–83. - PubMed
    1. Autran B, Carcelain G, Debre P. Immune reconstitution after highly active anti-retroviral treatment of HIV infection. Adv Exp Med Biol. 2001;495:205–12. - PubMed
    1. The UK Collaborative HIV Cohort (CHIC) Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med. 2004;5:115–24. - PubMed
    1. International Collaboration on HIV Cancer: Highly Active Anti-retroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults. J Natl Cancer Inst. 2000;92:1823–30. - PubMed

Publication types

MeSH terms